Christopher John Wilson
Christopher John Wilson
Stylus, Editas, Novartis, MIT, Arqule, Akceli
Verified email at
Cited by
Cited by
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
J Barretina, G Caponigro, N Stransky, K Venkatesan, AA Margolin, S Kim, ...
Nature 483 (7391), 603-307, 2012
Genome-wide location and function of DNA binding proteins
B Ren, F Robert, JJ Wyrick, O Aparicio, EG Jennings, I Simon, J Zeitlinger, ...
Science Signalling 290 (5500), 2306, 2000
Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling
SMA Huang, YM Mishina, S Liu, A Cheung, F Stegmeier, GA Michaud, ...
Nature 461 (7264), 614-620, 2009
Bidirectional transport of amino acids regulates mTOR and autophagy
P Nicklin, P Bergman, B Zhang, E Triantafellow, H Wang, B Nyfeler, ...
Cell 136 (3), 521-534, 2009
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
CM Johannessen, JS Boehm, SY Kim, SR Thomas, L Wardwell, ...
Nature 468 (7326), 968-972, 2010
Selective VPS34 inhibitor blocks autophagy and uncovers a role for NCOA4 in ferritin degradation and iron homeostasis in vivo
WE Dowdle, B Nyfeler, J Nagel, RA Elling, S Liu, E Triantafellow, ...
Nature cell biology 16 (11), 1069-1079, 2014
Development of a gene-editing approach to restore vision loss in Leber congenital amaurosis type 10
ML Maeder, M Stefanidakis, CJ Wilson, R Baral, LA Barrera, ...
Nature medicine 25 (2), 229-233, 2019
Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor
SM Maira, S Pecchi, A Huang, M Burger, M Knapp, D Sterker, C Schnell, ...
Molecular cancer therapeutics 11 (2), 317-328, 2012
Temporal regulation of RNA polymerase II by Srb10 and Kin28 cyclin-dependent kinases
CJ Hengartner, VE Myer, SM Liao, CJ Wilson, SS Koh, RA Young
Molecular cell 2 (1), 43-54, 1998
RNA polymerase II holoenzyme contains SWI/SNF regulators involved in chromatin remodeling.
CJ Wilson, DM Chao, AN Imbalzano, GR Schnitzler, RE Kingston, ...
Cell 84 (2), 235, 1996
Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials
C Fritsch, A Huang, C Chatenay-Rivauday, C Schnell, A Reddy, M Liu, ...
Molecular cancer therapeutics 13 (5), 1117-1129, 2014
FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor
V Guagnano, A Kauffmann, S Wöhrle, C Stamm, M Ito, L Barys, A Pornon, ...
Cancer Discovery, 2012
Structure of the CAP-DNA complex at 2.5 Å resolution: a complete picture of the protein-DNA interface
G Parkinson, C Wilson, A Gunasekera, YW Ebright, RE Ebright, ...
Journal of molecular biology 260 (3), 395-408, 1996
Association of MTOR mutations with developmental brain disorders, including megalencephaly, focal cortical dysplasia, and pigmentary mosaicism
GM Mirzaa, CD Campbell, N Solovieff, CP Goold, LA Jansen, S Menon, ...
JAMA neurology 73 (7), 836-845, 2016
Class III phosphatidylinositol 4-kinase alpha and beta are novel host factor regulators of hepatitis C virus replication
J Borawski, P Troke, X Puyang, V Gibaja, SC Zhao, C Mickanin, ...
Journal of virology 83 (19), 10058-10074, 2009
PIKfyve, a class III PI kinase, is the target of the small molecular IL-12/IL-23 inhibitor apilimod and a player in Toll-like receptor signaling
X Cai, Y Xu, AK Cheung, RC Tomlinson, A Alcázar-Román, L Murphy, ...
Chemistry & biology 20 (7), 912-921, 2013
Lehá r, J., Kryukov, GV, Sonkin, D., et al.(2012)
J Barretina, G Caponigro, N Stransky, K Venkatesan, AA Margolin, S Kim, ...
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer …, 0
Characterization of the mechanism of action of the pan class I PI3K inhibitor NVP-BKM120 across a broad range of concentrations
SM Brachmann, J Kleylein-Sohn, S Gaulis, A Kauffmann, MJJ Blommers, ...
Molecular cancer therapeutics 11 (8), 1747-1757, 2012
A strategy for rapid, high-confidence protein identification
J Qin, D Fenyö, Y Zhao, W William, DM Chao, CJ Wilson, RA Young, ...
Analytical chemistry 69 (19), 3995-4001, 1997
Pan-PIM kinase inhibition provides a novel therapy for treating hematologic cancers
PD Garcia, JL Langowski, Y Wang, M Chen, J Castillo, C Fanton, M Ison, ...
Clinical cancer research 20 (7), 1834-1845, 2014
The system can't perform the operation now. Try again later.
Articles 1–20